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Abstract
Introduction: Common variable immunodeficiency (CVID) is a form of severe antibody deficiency
with an estimated prevalence of 1 in 25,000 to 1 in 100,000. The disorder apparently results from
currently undefined immune deregulations resulting in failed B-cell differentiation with impaired
secretion of immunoglobulins. It has a broad range of clinical symptoms including recurrent
infections of the respiratory tract, chronic lung disease, autoimmune diseases, liver and
gastrointestinal disorders, granulomatous infiltrations, lymphoma and solid tumors.
Case presentation: A 42-year-old Caucasian female presented with a one-day history of high-
grade fever and productive cough associated with retrosternal chest pain. The patient had been
discharged one week prior after a prolonged stay in an intensive care unit with multiorgan failure
requiring temporary hemodialysis for two weeks secondary to sepsis. Past medical history was
significant for chronic obstructive pulmonary disease, recurrent pneumonias and recurrent sinus
infections since adolescence. She had a temperature of 99.8°F, was tachycardic (137/min),
tachypneic (26/min) with a blood pressure of 109/59 mmHg and oxygen saturation of 88% on 2 l/
min nasal oxygen. Physical examination was significant for bibasilar rhonchi. Laboratory data were
significant for leukocytosis of 15,700/mm3. Chest X-ray demonstrated bibasilar infiltrates. The
patient was started on intravenous levofloxacin and vancomycin, and sputum gram stain and
cultures were performed. Given the patient's recurrent respiratory infections, an underlying
immunologic disorder was considered. Work-up revealed immunoglobulin A (IgA) 11 mg/dl
(normal 70–400 mg/dl), immunoglobulin M (IgM) 2 mg/dl (normal 40–230 mg/dl) and IgG 53 mg/dl
(normal 700–1,600 mg/dl). The patient was diagnosed with CVID and started on intravenous
immunoglobulin. She was initially started on a four-week regimen of intravenous immunoglobulin,
which was later switched to a three-week regimen as the patient had respiratory infections on the
four-week regimen. She remained asymptomatic on a three times/week intravenous
immunoglobulin regimen.
Conclusion: This case emphasizes the need for a high index of clinical suspicion for CVID in
patients presenting with recurrent sinopulmonary infections. Although intravenous
immunoglobulin provides improvement in these patients, early diagnosis is the key to preventing
significant morbidity and mortality and improving prognosis.
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Introduction
Common variable immunodeficiency (CVID) is a form of
severe antibody deficiency with an estimated prevalence
of 1 in 25,000 to 1 in 100,000. The disorder results from
failed B-cell differentiation with impaired secretion of
immunoglobulins. It has a broad range of clinical mani-
festations including recurrent infections of the respiratory
tract and chronic lung disease, autoimmune diseases, gas-
trointestinal disorders, granulomatous infiltrative dis-
eases, lymphoma and solid tumors. We report a case of a
42-year-old Caucasian female who had presented with
classical symptoms of CVID over a period of several years
and review the various clinical manifestations, diagnosis
and treatment options for CVID.
Case presentation
A 42-year-old Caucasian female presented with a history
of high-grade fever and yellow productive cough for one
day. The cough was associated with pleuritic chest pain
and shortness of breath at rest. The patient described
chronic dyspnea for approximately 15 years limiting her
ability to perform household activities. A review of sys-
tems was significant for chronic fatigue and weakness for
15 years, and chronic loose stools with occasional consti-
pation for 10 years. The patient had been transferred from
the hospital to a rehabilitation facility one week prior fol-
lowing a prolonged stay in the intensive care unit with
multiorgan failure secondary to septic shock. She required
ventilatory support for two weeks and temporary hemodi-
alysis for approximately two weeks secondary to acute
kidney injury. She was discharged in a stable condition.
Past medical history included asthma for 15 years, chronic
obstructive pulmonary disease for 5 years, recurrent cough
and sinus infections since adolescence requiring antibiot-
ics, severe ear infection requiring emergent mastoidec-
tomy 4 years prior, gastroesophageal reflux disease,
irritable bowel syndrome for 10 years, migraine head-
aches and bipolar disorder for 2–3 years, and tonsillec-
tomy as a child. She had a normal mammogram 4 years
prior and a normal colonoscopy approximately 10 years
prior, which was performed as part of a work-up for irrita-
ble bowel syndrome. She admitted to a 20 pack year
smoking history, but denied any alcohol or illicit drug
abuse. Medications included levalbuterol, montelukast,
fluticasone/salmeterol for 10–15 years, lansoprazole and
loratidine/pseudoephedrine as required for a few years,
and hydrocodone, quetiapine fumarate and topiramate
for approximately 3 years.
On examination, she appeared chronically ill and anx-
ious. She had a temperature of 99.8°F, was tachycardic
(137/min), tachypneic (26/min) with a blood pressure of
109/59 mmHg and was saturating 88% on 2 l/min nasal
oxygen. Physical examination was significant for bibasilar
rhonchi and a central venous catheter in the left internal
jugular vein, which had been placed for hemodialysis. She
had no clubbing or nasal polyps. The remainder of the
physical examination was within normal limits.
Her white blood cell (WBC) count was elevated at 15,800/
mm3; this was 8,000/mm3 at discharge. Her blood urea
nitrogen (BUN) and creatinine levels were slightly ele-
vated at 24/1.6 mg/dl; however, these were on a down-
ward trend since discharge (29/2.4 mg/dl). Chest X-ray
was significant for improving bibasilar infiltrates when
compared with a previous chest X-ray at the time of dis-
charge. Cardiac enzymes were normal and arterial blood
gas (ABG) showed a pH of 7.5, PC02 of 32 mmHg, PO2 of
48 mmHg and HCO3 of 25 mEq/l on 2 l/min nasal oxy-
gen. The A-a gradient was markedly increased at 104
mmHg. Computerized tomography (CT) of the chest fol-
lowing the pulmonary embolism protocol did not reveal
any evidence of pulmonary embolism. Sputum Gram
stain with cultures and blood cultures were sent for anal-
ysis and she was started on intravenous levofloxacin and
vancomycin.
A high-resolution CT thorax scan without contrast was
carried out for better delineation of lung parenchyma and
was significant for bronchial wall thickening and dilata-
tion predominantly in the lower lung fields consistent
with bronchiectasis (Figure 1).
A CT scan of the sinuses revealed chronic maxillary sinusi-
tis. The patient showed clinical improvement by the next
day and the blood culture did not have any growth at 72
CT scan of the chest Figure 1
CT scan of the chest. Bronchial wall thickening and dilata-
tion predominantly in the lower lung zones consistent with 
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hours. Sputum culture showed moderate growth of Strep-
tococcus pneumoniae.
Given the patient's recurrent respiratory infections since
adolescence and bronchiectasis, a wide differential diag-
nosis was considered to include genetic conditions such as
cystic fibrosis, immotile cilia syndrome, alpha 1 antit-
rypsin deficiency and immunodeficiency. A work-up was
initiated which revealed a negative sweat chloride test and
normal alpha 1 antitrypsin levels. Human immunodefi-
ciency virus (HIV) screening test was negative. Ig levels
were significantly reduced: IgA 11 mg/dl (normal 70–400
mg/dl), IgM 2 mg/dl (normal 40–230 mg/dl) and IgG 53
mg/dl (normal 700–1,600 mg/dl). The presumptive diag-
nosis of CVID was confirmed by an inadequate antibody
response to pneumococcal vaccine and tetanus toxoid.
The patient was given 400 mg/kg of intravenous immu-
noglobulin (IVIG). She was initially started on a four-
week regimen of IVIG infusion, which was later switched
to a three-week regimen as the patient had respiratory
infections on the four-week regimen. Since initiation of
this regimen 18 months ago, the patient has required no
hospital admissions or antibiotic treatments and reported
a significant improvement in quality of life.
Discussion
CVID is a rare form of severe antibody deficiency with an
incidence of 1 in 25,000 to 1 in 100,000. The mean age of
diagnosis is 30 years, although there can be a delay in
diagnosis by many years as demonstrated in our patient
[1]. The disorder results from failed B-cell differentiation.
Thus, plasma cells do not develop and immunoglobulin
secretion is impaired. A number of defects of T-cell func-
tion and deficits in the memory B-cell pool have been
identified, but the underlying cause of this defect remains
unknown [1].
CVID has variable clinical manifestations, the most com-
mon being recurrent bacterial infections caused by encap-
sulated bacteria [1]. Bacterial infections commonly
involve the sinuses and respiratory tract leading to sinusi-
tis, otitis media, bronchitis and pneumonia. Chronic
sinusitis and bronchiectasis are frequent complications in
untreated patients leading to significant morbidity and
mortality [1]. Giardiasis is a frequent infection in patients
leading to chronic diarrhea. They can also have diarrhea
secondary to dysgonic fermenter 3, which is unusual in
immunocompetent patients [2]. They are prone to severe
herpes simplex, cytomegalovirus infections of the gas-
trointestinal tract [3,4] and meningoencephalitis from
enteroviral infection. Patients who are not receiving IVIG
owing to a delay in diagnosis may develop sepsis or men-
ingitis, which can be fatal [1]. These patients are also at
higher risk of developing other autoimmune diseases such
as thrombocytopenic purpura, hemolytic anemia and/or
neutropenia [5]. In the largest published case series of 248
patients, a 7.7% incidence of non-Hodgkin's lymphoma
(NHL) was reported [1]. Mucosal associated lymphoid tis-
sue lymphomas, an uncommon form of NHL, can occur
in these patients in the stomach or bronchial tissue [6,7].
Other uncommon manifestations include granulomatous
lung disease, follicular bronchiolitis, inflammatory bowel
disease, sprue-like illness, nodular lymphoid hyperplasia
and lymphoid interstitial pneumonia [8].
CVID should be suspected in any patient with recurrent
infections, especially of the upper or lower respiratory
tract. IgG, IgA or IgM levels should be less than two stand-
ard deviations below the mean for age-adjusted standard-
ized reference. They should also have inadequate
antibody response to pneumococcal vaccine and tetanus
toxoid or absent isohemagglutinins to confirm the diag-
nosis [9].
The mainstay of treatment is IVIG. The target trough level
should be 400–500 mg/dl, which is achieved by infusing
a dose of 200–400 mg/kg every three or four weeks. The
dosage varies from patient to patient, and IgG levels
should be checked periodically to attain a target trough
level. Autoimmune and granulomatous components of
this disease do not respond to treatment with IVIG. There
has been recent interest in the use of tumor necrosis factor
(TNF) antagonists and anti-CD20 immunomodulators in
treating autoimmune and granulomatous diseases based
on the dramatic improvement of some clinical manifesta-
tions documented in some case reports [10-12]. However,
long-term immunomodulators should be used with
extreme caution as these patients are at high risk of devel-
oping malignancies.
Conclusion
The case presented here emphasizes the need for a high
index of clinical suspicion for CVID in patients presenting
with recurrent sinopulmonary infections. Although IVIG
provides improvement in these patients, early diagnosis is
the key to preventing significant morbidity and mortality
and improving prognosis.
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